Evaluating quality of life in patients with asthma and rhinitis: English adaptation of the rhinasthma questionnaire (original) (raw)
Related papers
Allergy, 2007
Health-related quality of life (HRQOL) questionnaires are increasingly used in a variety of clinical and research settings including clinical trials, health surveys, clinical practice, and economic analyses of health care interventions (1, 2). Such measures are generally multidimensional (3) and include the measurement of symptoms, functional limitations, general health perceptions, and psychological well-being (4). The importance of HRQOL measurement in rhinitis is indicated by the fact that the World Health Organization's Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines base the classification of rhinitis severity on the impact of the disease on daily life (5). Several instruments have been developed to measure HRQOL in rhinoconjunctivitis and allergic rhinitis (AR) (6-8). One of the most frequently used is the Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ). The original version of the questionnaire, which consists of 28 items in seven dimensions, has proved its usefulness and validity (9-12). A shorter version of the questionnaire Background: We compared the psychometric properties of the ESPRINT-15, the short form of a new Spanish instrument to measure health-related quality of life in allergic rhinitis (AR) patients, with those of the Mini-Rhinoconjunctivitis Quality of Life Questionnaire (MiniRQLQ). Methods: The questionnaires were compared in Spanish patients with intermittent allergic rhinitis (IAR) or persistent AR in a prospective, observational study. Floor and ceiling effects, internal consistency (Cronbach's alpha), testretest reliability (intraclass correlation coefficient; ICC), convergent and known groups validity, and sensitivity to change (standardized response means; SRMs) were compared. Results: In terms of content, while the MiniRQLQ has a dimension covering practical problems and places more emphasis on symptoms, the ESPRINT-15 has two dimensions (Sleep and Psychological impact) which are not included in the MiniRQLQ. In the validation study, 400 patients were included and 59% of the sample had persistent AR. There were no significant floor or ceiling effects on any dimension on either questionnaire. Cronbach's alpha values for the ESPRINT-15 and MiniRQLQ overall scores were 0.92 and 0.90, respectively. In 48 clinically stable patients, ICCs were 0.80 and 0.77, respectively. Both instruments discriminated between patients with IAR and persistent AR. Correlations with symptom scores and generic measures were moderate to strong. SRMs for overall scores and individual dimensions on the two questionnaires in the 197 patients reporting a change in health status ranged from 0.7 to 1.3. Conclusions: Both questionnaires performed well in psychometric terms. The ESPRINT-15 is particularly recommended for use in Spanish-speaking populations.
Journal of Clinical Epidemiology, 2001
To test the metric proprieties of the Spanish version of the Juniper Asthma Quality of Life Questionnaire (AQLQ), we studied 116 adult asthmatic patients with a wide range of disease severity (53 patients were recruited from the respiratory outpatient department, 38 from a primary health care centre and 25 were patients admitted into hospital due to acute asthma). The patients were assessed twice, at recruitment and after 2 months. The AQLQ showed a high internal consistency (Cronbach's alpha ϭ 0.78 to 0.96) and a high 2-week reproducibility (ICC ϭ 0.82 to 0.92). Expected significant differences in AQLQ scores were observed according to disease severity as measured by symptoms, medication, use of services and recruitment setting. The cross-sectional and longitudinal correlations between AQLQ and the overall St. George's Respiratory Questionnaire were strong, moderate to strong between AQLQ and dyspnea and weak to moderate between AQLQ and FEV 1. The changes in AQLQ scores were significantly different in patients who either improved or deteriorated from those patients who remained stable (P Ͻ .0001 and P Ͻ .01, respectively, for the overall AQLQ). We conclude that the Spanish version of the AQLQ is reliable, valid and sensitive to changes.
tuberktoraks.org
Asthma quality of life questionnaire" yaşam kalitesi anketinin erişkin astımlı Türk hasta örneğinde geçerliliği ve güvenilirliği Çalışmamızda Astım yaşam kalitesi anketi [Asthma Quality of Life Questionnaire (AQLQ)]'nin Türkçe sürümünün erişkin astımlı Türk hastalarda geçerliliği ve güvenilirliğinin araştırılması amaçlanmıştır. Astım için küresel girişim [Global Initiative for Asthma (GINA)] 2008 kriterlerine göre daha önceden veya yeni tanı almış 18-55 yaş arası stabil dönemde, semptomatik, ardışık 118 astım hastası çalışmaya alındı. Hastaların astım ağırlığı belirlendi ve AQLQ anketinin Türkçe adaptasyonu uygulandı. Aynı zamanda Lara astım semptom skorları (LASS), solunum fonksiyon testleri, "Medical Outcomes Survey Short Form-36 (SF-36)" Türkçe adaptasyonu değerlendirildi. Tüm uygulamalar başlangıçta ve 10. haftada yapıldı. Bu süreç içinde hastalar tedavilerini gereğinde değiştirmekte serbest bırakıldılar. Çalışmaya alınan 118 hastanın 95'i kadındı, 14 hasta takipte değerlendirilemedi. Hastaların %62'si hafif, %38'si orta-ağır astım grubundaydı. AQLQ iç uyumluluğu yüksekti (Cronbach's alpha 0.81-0.87) ve soru-toplam skor korelasyonları 0.75-0.89 arasında değişmekteydi. AQLQ alan ve toplam skorları ile SF-36 alan skorları arasındaki kesitsel ve izlemsel ilişki az veya orta derece arasında değişmekteydi (r= 0.241-0.626, p< 0.005). AQLQ değerleri astım ağırlığı ve LASS'ye göre birinci (p< 0.001, her ikisi için) ve 10. hafta vizitlerinde (p= 0.006, p< 0.001 sırasıyla) anlamlı derecede farklılık göstermekteydi. İzlemde LASS'nin anlamlı değişiklik göstermesine paralel olarak, AQLQ'nun semptom domaininde anlamlı değişiklik olduğu saptandı (p< 0.001). Sonuçlarımız AQLQ'nun Türkçe sürümünün erişkin astımlı Türk hastalarda uygulanabilir, geçerli ve güvenilir olduğunu ortaya koymuştur.
Journal of Medical Internet Research
Background: The EuroQol-5 Dimension (EQ-5D), developed in 1990, is a most widely used generic tool to measure the health-related quality of life (HRQoL) and considered suitable for patients with asthma. In 2009, the EuroQol Group developed a new EQ-5D version to overcome limitations related to its consistently reported high ceiling effect. To enhance the sensitivity for assessing the HRQoL in further patient populations, the number of responses of EQ-5D was increased from 3 to 5 levels (EQ-5D-5L). Moreover, the availability of well-defined requirements for its Web-based administration allows EQ-5D-5L use to monitor the HRQoL in electronic health (eHealth) programs. No study has evaluated the metric properties of the new EQ-5D-5L in patients with asthma yet. Objective: This study aims to examine the distribution, construct validity, and reliability of the new EQ-5D-5L questionnaire administered online to adults with asthma. Methods: We evaluated patients with asthma (age: 18-40 years) from a primary care setting in France and England, who self-completed the EQ-5D-5L questionnaire online. The inclusion criteria were persistent asthma defined as >6 months of prescribed inhaled corticosteroids and long-acting beta-agonists or inhaled corticosteroids alone during the 12 months prior to inclusion. The EQ-5D index was obtained by applying the English preference value set for the new EQ-5D-5L and the French 3L-5L crosswalk value set. Both value sets produced single preference-based indices ranging from 1 (best health state) to negative values (health states valued as worse than death), where 0=death, allowing the calculation of quality-adjusted life years. Responses to dimensions and index distribution, including ceiling and floor effects, were examined. The construct validity was assessed by comparing the means of known groups by analyses of variance and calculation of effect sizes. Results: Of 312 patients answering the baseline Web-based survey, 290 completed the EQ-5D-5L (93%). The floor effect was null, and the ceiling effect was 26.5% (74/279). The mean EQ-5D-5L index was 0.88 (SD 0.14) with the English value set and 0.83 (SD 0.19) with the French 3L-5L crosswalk value set. In both indices, large effect sizes were observed for known groups defined by the Asthma Control Questionnaire (1.06 and 1.04, P<.001). Differences between extreme groups defined by chronic
Quality-of-life and asthma-severity in general population asthmatics: results of the ECRHS II study
Allergy, 2008
Many studies conducted both in clinical and populationbased samples show that the quality-of-life is impaired in asthmatic patients (1-3). One of the major goals in the management of asthma is to improve the health-related quality-of-life (HRQL) of patients. Standardized questionnaires, either generic applied over all diseases or specific for asthma, have been developed in tandem with clinical criteria to measure the impact of the disease on daily life in clinical trials (4, 5). Results from Juniper et al. (6) indicated that HRQL measures add complementary information to conventionally-used clinical outcomes. There are few data on HRQL in asthmatics selected from community-based samples and determinants of HRQL remain poorly addressed. Although the quality-of-life decreased with the degree of asthma-severity (7, 8), HRQL is not simply a further index of severity, as the degree to which disease is perceived to affect daily life may vary between patients with the same asthma-severity.
Multidisciplinary Respiratory Medicine, 2015
Background: Asthma and chronic obstructive pulmonary disease (COPD) are frequent in the general population. These diseases can worsen the quality of life of people suffering from them, limiting their daily activities and disrupting their sleep at night. Some questionnaires to measure the impact of the diseases on the daily life of patients are available. The measurements of subjective outcomes have become a part of clinical practice, and are used very frequently in clinical trials. Our aim was to describe how data on HRQoL in asthma and COPD are reported in papers published in the medical literature. Methods: We identified papers on the recent respiratory drugs (chemical, not biological), that reported the HRQoL measurement and that were published from 2009 to April 2014. We planned to describe data about HRQoL, and we had no intention of comparing the degree of efficacy of drugs. Results: The most used questionnaires are the Asthma Quality of Life Questionnaire (AQLQ) and the Saint George's Respiratory Questionnaire (SGRQ). These tools, administered at the baseline and at the end of the study (and interim evaluations in the longer studies) allowed for the identification of improvements as perceived by the patient after the treatment, even if in some cases these improvements were limited and not clinically relevant. Subjective measurements have always been placed among the secondary endpoints and the number of patients (estimated for the main endpoint) has often statistically overestimated the result. In addition, it is clear that subjective data is normally reported, but rarely commented on. Conclusions: There are some methodology aspects that should be discussed in more depth, for example the necessity to express variations in the subjective perception, not as p-value but as effect-size.